A recent study has demonstrated potential for lexaptepid pegol as the first treatment for anemia of inflammation, the most common form of anemia. The results are published in the American Society of Hematology’s journal, Blood.
Currently, the only treatment strategy for anemia of inflammation is to target the underlying disease or infection. Hepcidin, the main regulator of iron, has become the target for researchers developing investigational drugs for blood disorders. Lexaptepid pegol is an investigational hepcidin inhibitor that helps to maintain iron transport to the bloodstream.
Study investigators induced a temporary model of anemia of inflammation in healthy male adults (n=24) and randomized them to either lexaptepid pegol or placebo. Patients initially received a low dose of Escherichia coli (E. Coli) endotoxin to induce the controlled inflammation and then received either lexaptepid pegol or placebo 30 minutes later. Results showed that iron levels had decreased in the bloodstream in the placebo group, whereas the decrease could be prevented with lexaptepid pegol. Researchers also found that the study drug did not interfere with the immune response process.
For more information visit BloodJournal.org.